{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:18:18Z","timestamp":1790144298573,"version":"4.0.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.suc.2013.01.005","type":"journal-article","created":{"date-parts":[[2013,2,11]],"date-time":"2013-02-11T23:23:03Z","timestamp":1360624983000},"page":"341-362","source":"Crossref","is-referenced-by-count":28,"title":["Genetic Predisposition Syndromes and Their Management"],"prefix":"10.1016","volume":"93","author":[{"given":"David M.","family":"Euhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suc.2013.01.005_bib1","series-title":"Traite pratique des maladies cancereuses","author":"Lebert","year":"1851"},{"key":"10.1016\/j.suc.2013.01.005_bib2","first-page":"3","article-title":"Versuche \u00fcber Pflanzenhybriden Verh","volume":"4","author":"Mendel","year":"1865","journal-title":"Naturforscher-Verein Br\u00fcnn"},{"key":"10.1016\/j.suc.2013.01.005_bib3","first-page":"441","article-title":"Ueber die chemische Zusammensetzung der Eiterzellen","volume":"4","author":"Miescher","year":"1871","journal-title":"Medicinisch-Chemische Untersuchungen"},{"key":"10.1016\/j.suc.2013.01.005_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.79.2.137","article-title":"Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III","volume":"79","author":"Avery","year":"1944","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.suc.2013.01.005_bib5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1159\/000133177","article-title":"Report of the Committee on the Genetic Constitution of Chromosome 17","volume":"58","author":"Solomon","year":"1991","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.suc.2013.01.005_bib7","series-title":"Traite des tumeurs","author":"Broca","year":"1866"},{"key":"10.1016\/j.suc.2013.01.005_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"issue":"5182","key":"10.1016\/j.suc.2013.01.005_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A\u00a0strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"5181","key":"10.1016\/j.suc.2013.01.005_bib10","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.suc.2013.01.005_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.suc.2013.01.005_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng0396-333","article-title":"The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds","volume":"12","author":"Tavtigian","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc970","article-title":"The Fanconi anemia\/BRCA pathway","volume":"3","author":"D\u2019Andrea","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib14","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","article-title":"Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer","volume":"71","author":"Casadei","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.suc.2013.01.005_bib15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.4161\/cbt.5.12.3658","article-title":"Disruption of the Fanconi anemia pathway in human cancer in the general population","volume":"5","author":"Jacquemont","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.suc.2013.01.005_bib16","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/carcin\/bgi360","article-title":"RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability","volume":"27","author":"Heikkinen","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.suc.2013.01.005_bib17","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-08-0087","article-title":"A\u00a0novel breast cancer\u2013associated BRIP1 (FANCJ\/BACH1) germ-line mutation impairs protein stability and function","volume":"14","author":"De Nicolo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suc.2013.01.005_bib18","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","article-title":"Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome","volume":"286","author":"Bell","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.suc.2013.01.005_bib19","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/92.15.1260","article-title":"High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families","volume":"92","author":"Borg","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib20","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-08-0403","article-title":"Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families","volume":"14","author":"de Snoo","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.suc.2013.01.005_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/gim.2012.51","article-title":"Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome","volume":"14","author":"Mester","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.suc.2013.01.005_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/hmg\/7.3.507","article-title":"Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation","volume":"7","author":"Marsh","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jmg.2009.074237","article-title":"Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research","volume":"47","author":"Fitzgerald","year":"2010","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10689-007-9172-6","article-title":"Hereditary diffuse gastric cancer: association with lobular breast cancer","volume":"7","author":"Schrader","year":"2008","journal-title":"Fam Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib25","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","article-title":"Frequency and spectrum of cancers in the Peutz-Jeghers syndrome","volume":"12","author":"Hearle","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suc.2013.01.005_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.bjc.6600008","article-title":"A\u00a0comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes","volume":"86","author":"Antoniou","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","article-title":"Founder BRCA1\/2 mutations in Europe: implications for hereditary breast-ovarian cancer prevention and control","volume":"1","author":"Janavicius","year":"2010","journal-title":"EPMA J"},{"key":"10.1016\/j.suc.2013.01.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-4-1","article-title":"Frequency of CHEK2*1100delC in New York breast cancer cases and controls","volume":"4","author":"Offit","year":"2003","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/341943","article-title":"A\u00a0CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer","volume":"71","author":"Vahteristo","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","article-title":"Genome-wide association study identifies novel breast cancer susceptibility loci","volume":"447","author":"Easton","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.suc.2013.01.005_bib31","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1056\/NEJMsa0708739","article-title":"Polygenes, risk prediction, and targeted prevention of breast cancer","volume":"358","author":"Pharoah","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2013.01.005_bib32","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1158\/0008-5472.CAN-10-1907","article-title":"Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction","volume":"70","author":"Antoniou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.suc.2013.01.005_bib33","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3052","article-title":"Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2","volume":"13","author":"Mulligan","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.suc.2013.01.005_bib34","unstructured":"Eggington JM, Burbridge LA, Roa B, et\u00a0al. Current variant of uncertain significance rates in BRCA1\/2 and Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EpCam). American College of Medical Genetics Annual Clinical Genetics Meeting. Charlotte, March 27\u201331, 2012."},{"key":"10.1016\/j.suc.2013.01.005_bib35","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1086\/521032","article-title":"A\u00a0systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes","volume":"81","author":"Easton","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib37","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.294.15.1925","article-title":"Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry","volume":"294","author":"Nanda","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.suc.2013.01.005_bib38","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/1055-9965.EPI-05-0072","article-title":"Prevalence of BRCA mutations and founder effect in high-risk Hispanic families","volume":"14","author":"Weitzel","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.suc.2013.01.005_bib39","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1200\/JCO.2011.37.8133","article-title":"Breast and ovarian cancer risk and risk reduction in Jewish BRCA1\/2 mutation carriers","volume":"30","author":"Finkelman","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.suc.2013.01.005_bib40","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.27556","article-title":"Clinical significance of large rearrangements in BRCA1 and BRCA2","volume":"118","author":"Judkins","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10897-011-9462-x","article-title":"Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of\u00a0the National Society of Genetic Counselors","volume":"21","author":"Riley","year":"2012","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.suc.2013.01.005_bib42","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast and ovarian, NCCN Clinical Practice Guidelines in Oncology v.1.2012. Fort Washington (PA): 2012. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/genetics_screening.pdf. Accessed February 1, 2013."},{"key":"10.1016\/j.suc.2013.01.005_bib43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jnci\/89.3.227","article-title":"Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history","volume":"89","author":"Berry","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A\u00a0breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.suc.2013.01.005_bib45","unstructured":"Euhus DM. Cancer Gene 2012. Available at: http:\/\/www4.utsouthwestern.edu\/breasthealth\/cagene. Accessed February 1, 2013."},{"key":"10.1016\/j.suc.2013.01.005_bib46","unstructured":"Cleveland Clinic. Risk calculator for estimating a patient\u2019s risk for PTEN mutation. 2012. Available at: http:\/\/www.lerner.ccf.org\/gmi\/ccscore\/index.php. Accessed February 1, 2013."},{"key":"10.1016\/j.suc.2013.01.005_bib47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/0003-4819-147-7-200710020-00002","article-title":"Validity of models for predicting BRCA1 and BRCA2 mutations","volume":"147","author":"Parmigiani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.suc.2013.01.005_bib48","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","article-title":"Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO","volume":"94","author":"Euhus","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2296-11-45","article-title":"Primary care physicians' use of family history for cancer risk assessment","volume":"11","author":"Flynn","year":"2010","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.suc.2013.01.005_bib50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/GIM.0b013e3181d4bc3a","article-title":"Further development and evaluation of a breast\/ovarian cancer genetics referral screening tool","volume":"12","author":"Bellcross","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.suc.2013.01.005_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/GIM.0b013e3181b9b04a","article-title":"Evaluation of a breast\/ovarian cancer genetics referral screening tool in a mammography population","volume":"11","author":"Bellcross","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.suc.2013.01.005_bib52","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2006.24.18_suppl.508","article-title":"Prevalence of BRCA1 mutations in triple negative breast cancer","volume":"24","author":"Kandel","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the breast cancer linkage consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib54","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.suc.2013.01.005_bib56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1399-0004.2009.01328.x","article-title":"Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?","volume":"77","author":"Panchal","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib57","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/jmg.2004.024133","article-title":"Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies","volume":"42","author":"Antoniou","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10552-005-1724-1","article-title":"Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"16","author":"Kotsopoulos","year":"2005","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.suc.2013.01.005_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-005-9051-5","article-title":"Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland","volume":"95","author":"Gronwald","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10549-006-9441-3","article-title":"Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"105","author":"Kotsopoulos","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib61","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.21273","article-title":"Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers","volume":"117","author":"Cullinane","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jnci\/djh211","article-title":"Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"96","author":"Jernstrom","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib63","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ijc.21296","article-title":"Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers","volume":"118","author":"Nkondjock","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10549-006-9161-8","article-title":"Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians","volume":"98","author":"Nkondjock","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib66","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-008-9892-9","article-title":"Early radiation exposures and BRCA1-associated breast cancer in young women from Poland","volume":"112","author":"Gronwald","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","article-title":"Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition","volume":"351","author":"Kriege","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2013.01.005_bib68","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","article-title":"Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)","volume":"365","author":"Leach","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.suc.2013.01.005_bib69","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.suc.2013.01.005_bib70","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1148\/radiol.2423051965","article-title":"Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results","volume":"242","author":"Sardanelli","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.suc.2013.01.005_bib71","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1200\/JCO.2009.24.4277","article-title":"Multimodality screening of high-risk women: a prospective cohort study","volume":"27","author":"Weinstein","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.breast.2007.01.006","article-title":"Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series","volume":"16","author":"Hagen","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.suc.2013.01.005_bib73","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00330-009-1588-y","article-title":"Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts","volume":"20","author":"Kelly","year":"2010","journal-title":"Eur Radiol"},{"key":"10.1016\/j.suc.2013.01.005_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.suc.2013.01.005_bib75","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib76","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.suc.2013.01.005_bib77","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1200\/JCO.2005.01.9737","article-title":"Optimal selection of individuals for BRCA mutation testing: a comparison of available methods","volume":"24","author":"James","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib78","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib79","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.1998.16.5.1642","article-title":"BRCA-associated breast cancer in young women","volume":"16","author":"Robson","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib80","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib82","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.suc.2013.01.005_bib83","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1002\/cncr.25439","article-title":"The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations","volume":"116","author":"Norquist","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin Med Res"},{"key":"10.1016\/j.suc.2013.01.005_bib85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib86","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00000478-200110000-00009","article-title":"Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status","volume":"25","author":"Colgan","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.suc.2013.01.005_bib87","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2013.01.005_bib88","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1200\/JCO.2007.11.3449","article-title":"Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2","volume":"25","author":"Kauff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib89","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2011.254","article-title":"Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies","volume":"105","author":"Key","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib90","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.suc.2013.01.005_bib91","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib92","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib93","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib94","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","article-title":"Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic","volume":"14","author":"Heemskerk-Gerritsen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib95","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2013.01.005_bib96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2013.01.005_bib97","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1200\/JCO.2007.13.9568","article-title":"Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study","volume":"26","author":"Brandberg","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib98","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib99","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/bjs.6970","article-title":"Nipple-sparing mastectomy","volume":"97","author":"Rusby","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.suc.2013.01.005_bib101","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1524-4741.2012.01234.x","article-title":"Risk of residual breast tissue after skin-sparing mastectomy","volume":"18","author":"Dreadin","year":"2012","journal-title":"Breast J"},{"key":"10.1016\/j.suc.2013.01.005_bib102","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1245\/s10434-007-9568-4","article-title":"Terminal duct lobular units are scarce in the nipple: implications for prophylactic nipple-sparing mastectomy: terminal duct lobular units in the nipple","volume":"15","author":"Stolier","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib103","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","article-title":"Breast cancer risk among male BRCA1 and BRCA2 mutation carriers","volume":"99","author":"Tai","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib104","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.breast.2008.05.001","article-title":"Counseling for male BRCA mutation carriers: a review","volume":"17","author":"Mohamad","year":"2008","journal-title":"Breast"},{"key":"10.1016\/j.suc.2013.01.005_bib105","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1940-6207.CAPR-10-0397","article-title":"Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families","volume":"4","author":"Thorne","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.suc.2013.01.005_bib106","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1684\/bdc.2012.1552","volume":"99","author":"Brachot-Simeonova","year":"2012","journal-title":"Bull Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib107","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12609-012-0071-y","article-title":"Genetic counseling and genetic testing in the preoperative evaluation of breast cancer patients","volume":"4","author":"Euhus","year":"2012","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.suc.2013.01.005_bib108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejca.2006.07.019","article-title":"Management of BRCA1\/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006","volume":"43","author":"Liebens","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib109","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","article-title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","volume":"121","author":"Pierce","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-010-0859-2","article-title":"Effect of BRCA1\/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis","volume":"122","author":"Lee","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","article-title":"Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study","volume":"30","author":"Goodwin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib112","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1245\/s10434-009-0638-7","article-title":"Breast-conserving surgery in BRCA1\/2 mutation carriers: are we approaching an answer?","volume":"16","author":"Garcia-Etienne","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib113","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","article-title":"Outcome of conservatively managed early-onset breast cancer by BRCA1\/2 status","volume":"359","author":"Haffty","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.suc.2013.01.005_bib114","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijrobp.2009.02.031","article-title":"Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)","volume":"74","author":"Smith","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.suc.2013.01.005_bib115","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"104","author":"Metcalfe","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jnci\/djq018","article-title":"Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients","volume":"102","author":"Bedrosian","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2013.01.005_bib117","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1245\/s10434-010-1136-7","article-title":"Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer","volume":"17","author":"Boughey","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib118","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jmg.39.8.608","article-title":"A\u00a0significant response to neoadjuvant chemotherapy in BRCA1\/2 related breast cancer","volume":"39","author":"Chappuis","year":"2002","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib119","unstructured":"Delaloge S, Pautier P, Kloos I, et\u00a0al. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts, 27th Congress of the European Society for Medical Oncology. Nice (France): October 18\u201322, 2002."},{"key":"10.1016\/j.suc.2013.01.005_bib120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10689-008-9223-7","article-title":"Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer","volume":"8","author":"Hubert","year":"2009","journal-title":"Fam Cancer"},{"key":"10.1016\/j.suc.2013.01.005_bib121","first-page":"SC7","article-title":"Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations","volume":"14","author":"Wysocki","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.suc.2013.01.005_bib122","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-007-9600-1","article-title":"Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers","volume":"108","author":"Byrski","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib123","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ctrv.2007.07.013","article-title":"A\u00a0systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.suc.2013.01.005_bib124","first-page":"1169","article-title":"The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells","volume":"22","author":"Fedier","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib126","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-008-0128-9","article-title":"Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"115","author":"Byrski","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2013.01.005_bib127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2013.01.005_bib128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.suc.2013.01.005_bib129","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.suc.2013.01.005_bib130","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.suc.2013.01.005_bib131","unstructured":"Ambry Genetics. BreastNext. 2012. Available at: http:\/\/www.ambrygen.com\/tests\/breastnext. Accessed February 1, 2013."},{"key":"10.1016\/j.suc.2013.01.005_bib132","unstructured":"National Comprehensive Cancer Network. Colorectal Cancer Screening, NCCN Clinical Practice Guidelines in Oncology v2.2012. Fort Washington (PA): 2012. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed February 1, 2013."},{"key":"10.1016\/j.suc.2013.01.005_bib133","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/gut.2009.198499","article-title":"Peutz-Jeghers syndrome: a systematic review and recommendations for management","volume":"59","author":"Beggs","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.suc.2013.01.005_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2010.01402.x","article-title":"Testing for CHEK2 in the cancer genetics clinic: ready for prime time?","volume":"78","author":"Narod","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.suc.2013.01.005_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8019.2005.00050.x","article-title":"Cutaneous melanoma: family screening and genetic testing","volume":"19","author":"Niendorf","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.suc.2013.01.005_bib137","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1200\/JCO.1999.17.10.3245","article-title":"Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma genetics consortium","volume":"17","author":"Kefford","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2013.01.005_bib138","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10689-007-9166-4","article-title":"Pancreatic cancer and the FAMMM syndrome","volume":"7","author":"Lynch","year":"2008","journal-title":"Fam Cancer"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610913000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610913000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T05:44:18Z","timestamp":1595396658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610913000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0039610913000066"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2013.01.005","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}